MSD’s pembrolizumab approved by Scottish Medicines Consortium
The Scottish Medicines Consortium (SMC) has accepted MSD's KEYTRUDA®▼ (pembrolizumab) as monotherapy for the adjuvant treatment of adults with stage III melanoma with lymph...
Roche test detects antimicrobial resistance within TB
Roche has announced the CE-IVD launch of the cobas® MTB-RIF/INH test to detect resistance to antibiotics within tuberculosis DNA. This assay is part of the...
NHS experts band together to tackle ‘chemical cosh’ in care homes
An 'army' of health experts has been recruited by NHS England to help prevent care home residents being given too many medicines as charities...
State of the Discovery Nation report shares insights into UK medicines discovery industry
Medicines Discovery Catapult and the BioIndustry Association (BIA) have unveiled their 2019 State of the Discovery Nation report, providing new insights into the UK’s...
Bristol-Myers Squibb trial fails to meet primary endpoint
Bristol-Myers Squibb's Phase 3 CheckMate -498 trial evaluating Opdivo (nivolumab) plus radiation versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated...
Sanofi’s Dupixent® ▼ (dupilumab) licensed in EU
Sanofi has announced that Dupixent® ▼ (dupilumab) has been licensed in the EU for the treatment of severe asthma with type 2 inflammation. The European...
Obesity an increasing factor in hospital admissions
Admissions to NHS hospitals, where obesity was recorded as either a primary or secondary diagnosis, increased by 15% (94,000) in 2017/18 compared to 2016/17. The...
Pivotal Phase II DESTINY-Breast01 trial meets primary endpoint
AstraZeneca and Daiichi Sankyo have announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201). The HER2-targeting antibody drug conjugate...
MRC to run competition process for Digital Innovation Hubs
The MRC is to run a competition process on behalf of Health Data Research UK, to create Digital Innovation Hubs: centres of excellence dedicated...
Novartis announces results of MS Progression Discussion Tool
Novartis has announced results from a validation study of the algorithm-based digital solution MS Progression Discussion Tool, or MSProDiscussTM. The tool aims to support...
Latest articles
Biotech leader wins PING Innovation Award 2019
Dr Harry Destecroix of Ziylo has won the 2019 Pharmaceutical Industry Network Group (PING) Innovation Award, hosted by pharma and life sciences specialist law...
NICE recommend funding for Spinraza for spinal muscular atrophy
The National Institute for Health and Care Excellence (NICE) has recommended funding for Spinraza (nusinersen) on the National Health Service (NHS). The positive recommendation, subject to...
New data from Novel START trial accepted for presentation
New data from the Symbicort Turbuhaler (budesonide/formoterol) Novel START trial is among 73 AstraZeneca abstracts accepted for oral or poster presentation at the American...
Popular articles
Nurofen launches a 24 hour ibuprofen pain relief patch
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...
Novartis presents new migraine data for Aimovig®▼ (erenumab)
Novartis presents new migraine data for Aimovig®▼ (erenumab) demonstrating sustained efficacy to 52 weeks. Novartis has announced that new data from two follow-up studies of...
New data from Novel START trial accepted for presentation
New data from the Symbicort Turbuhaler (budesonide/formoterol) Novel START trial is among 73 AstraZeneca abstracts accepted for oral or poster presentation at the American...
Top 5 R&D hubs in the UK
Read this cover story in the June issue of Pf Magazine here. Join us on a tour of inspirational research and development centres. ...
Biotech leader wins PING Innovation Award 2019
Dr Harry Destecroix of Ziylo has won the 2019 Pharmaceutical Industry Network Group (PING) Innovation Award, hosted by pharma and life sciences specialist law...